Kidney Cancer Articles | Page 3

Nivolumab Sustains Survival Benefit in RCC at 3 Years
Nivolumab reduced the risk of death by 26% compared with everolimus in patients with previously treated advanced renal cell carcinoma.
Steps Being Taken to Turn mRCC Into a Chronic Disease
Daniel M. Geynisman, MD, discusses remaining challenges in the landscape of RCC, despite progress with systemic therapies and the pivotal ongoing studies combining immunotherapy and targeted therapy.
FDA Grants Priority Review to Frontline Cabozantinib in RCC
The FDA has granted a priority review to a supplemental new drug application for cabozantinib (Cabometyx) for previously untreated patients with advanced renal cell carcinoma.
Revised Guidelines Helping to Advance Kidney Cancer Care
Robert G. Uzzo, MD, discusses recent guidelines that have impacted clinical practice and ongoing biomarker research in the field of kidney cancer.
Novel Immunotherapy Approaches Moving Through RCC Pipeline
Matthew R. Zibelman, MD, discussed the promise of immunotherapy combinations for patients with kidney cancer.
Advanced RCC Results Point to Potentially New Frontline Treatments
Michael R. Harrison, MD, discusses emerging data that are likely to impact the treatment landscape for patients with RCC.
Debating the True Benefit of Adjuvant TKIs in High-Risk RCC
Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.
Rana R. McKay, MD, discusses the promising findings from the CheckMate-214 and CABOSUN studies in renal cell carcinoma. 
Choueiri Covers CABOSUN Excitement and Beyond in RCC
Toni K. Choueiri, MD, sheds light on the excitement surrounding the CABOSUN and CheckMate-214 trials, and why the future of the renal cell carcinoma field lies in novel combination regimens.
Pal Provides Key ESMO Updates in GU Malignancies
Sumanta Kumar Pal, MD, discusses the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.
Publication Bottom Border
Border Publication
x